Nephros director granted 2,418 shares as fees

Q: What did Nephros (NEPH) director Arthur H. Amron report in this Form 4?

Arthur H. Amron reported a grant of 2,418 shares of Nephros Common Stock on 2026-08-12, received in lieu of cash fees for board service, increasing his direct Common Stock holdings to 140,874 shares.

Q: How many Nephros (NEPH) shares does Arthur H. Amron now own directly?

After the reported grant, Arthur H. Amron directly holds 140,874 shares of Nephros Common Stock. This figure reflects the addition of 2,418 shares issued to him in lieu of cash compensation for his service on the board of directors.

Q: Were the new Nephros (NEPH) shares a purchase or compensation grant?

The 2,418 Nephros shares were issued to Arthur H. Amron in lieu of cash fees for board service, at a reported price of $0.00 per share, indicating a compensation-related grant rather than an open-market purchase.

Q: What stock options in Nephros (NEPH) does Arthur H. Amron hold?

Arthur H. Amron holds options to acquire 7,323 shares of Nephros Common Stock at $2.14 per share, which are fully vested, and additional options for 7,050 shares at $1.47 per share with a stated vesting schedule.

Q: What is the vesting schedule for Arthur H. Amron’s Nephros (NEPH) options at $1.47?

The option covering 7,050 shares at an exercise price of $1.47 per share vests as to 2,350 shares on each of 1/1/25, 1/1/26, and 1/1/27, according to the disclosed vesting footnote.

Q: Did Arthur H. Amron sell any Nephros (NEPH) shares in this Form 4?

The Form 4 reports no sales of Nephros Common Stock by Arthur H. Amron. It shows a grant of 2,418 shares for board service and discloses his existing stock option positions and vesting terms without any reported dispositions.

Nephros Inc. director Arthur H. Amron received 2,418 shares of Common Stock on 2026-08-12 as a grant in lieu of cash fees for board service, bringing his direct Common Stock holdings to 140,874 shares.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Nephros Inc. director Arthur H. Amron received 2,418 shares of Common Stock on 2026-08-12 as a grant in lieu of cash fees for board service, bringing his direct Common Stock holdings to 140,874 shares. He also holds stock options to acquire 7,323 shares of Common Stock at an exercise price of $2.14 per share that are fully vested, and additional options for 7,050 shares at an exercise price of $1.47 per share that vest in three equal installments of 2,350 shares on 1/1/25, 1/1/26 and 1/1/27.

Insider Trade Summary

Grant/Award: 2,418 shares

Grant/Award 3 txns

Insider Amron Arthur H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock ^F1	2,418	$0.00	$0.00
holding	Stock Option (Right to Buy) ^F2	--	--	--
holding	Stock Option (Right to Buy) ^F3	--	--	--

Holdings After Transaction: Common Stock — 140,874 shares (Direct); Stock Option (Right to Buy) — 14,373 contracts (Direct)

Footnotes (3)

F1. Shares issued to reporting person in lieu of cash fees for board service.
F2. Fully vested.
F3. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.

Key Figures

Common Stock grant: 2,418 shares Holdings after grant: 140,874 shares Option exercise price: $2.14 per share +3 more

6 metrics

Common Stock grant 2,418 shares Shares issued on 2026-08-12 in lieu of cash fees for board service

Holdings after grant 140,874 shares Total direct Common Stock owned by Arthur H. Amron following the grant

Option exercise price $2.14 per share Exercise price for fully vested stock option on 7,323 underlying Common shares

Option exercise price $1.47 per share Exercise price for stock option on 7,050 underlying Common shares vesting 2025-2027

Underlying shares (fully vested option) 7,323 shares Common Stock underlying fully vested stock option at $2.14 per share

Underlying shares (vesting option) 7,050 shares Common Stock underlying option at $1.47 per share vesting in three 2,350-share tranches

Key Terms

in lieu of cash fees, fully vested, Stock Option (Right to Buy), exercise price, +1 more

5 terms

in lieu of cash fees financial

"Shares issued to reporting person in lieu of cash fees for board service."

fully vested financial

"Fully vested."

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with underlying Common Stock and exercise price."

exercise price financial

"exercise price of $2.1400 and $1.4700 per share on stock options."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying security shares of Common Stock for the stock options."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nephros (NEPH) director Arthur H. Amron report in this Form 4?

Arthur H. Amron reported a grant of 2,418 shares of Nephros Common Stock on 2026-08-12, received in lieu of cash fees for board service, increasing his direct Common Stock holdings to 140,874 shares.

How many Nephros (NEPH) shares does Arthur H. Amron now own directly?

After the reported grant, Arthur H. Amron directly holds 140,874 shares of Nephros Common Stock. This figure reflects the addition of 2,418 shares issued to him in lieu of cash compensation for his service on the board of directors.

Were the new Nephros (NEPH) shares a purchase or compensation grant?

The 2,418 Nephros shares were issued to Arthur H. Amron in lieu of cash fees for board service, at a reported price of $0.00 per share, indicating a compensation-related grant rather than an open-market purchase.

What stock options in Nephros (NEPH) does Arthur H. Amron hold?

Arthur H. Amron holds options to acquire 7,323 shares of Nephros Common Stock at $2.14 per share, which are fully vested, and additional options for 7,050 shares at $1.47 per share with a stated vesting schedule.

What is the vesting schedule for Arthur H. Amron’s Nephros (NEPH) options at $1.47?

The option covering 7,050 shares at an exercise price of $1.47 per share vests as to 2,350 shares on each of 1/1/25, 1/1/26, and 1/1/27, according to the disclosed vesting footnote.

Did Arthur H. Amron sell any Nephros (NEPH) shares in this Form 4?

The Form 4 reports no sales of Nephros Common Stock by Arthur H. Amron. It shows a grant of 2,418 shares for board service and discloses his existing stock option positions and vesting terms without any reported dispositions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/14/2026 - 04:12 PM Accepted by SEC EDGAR 08/14/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Amron Arthur H

(Last)

(First)

(Middle)

C/O NEPHROS, INC., 380 LACKAWANNA PLACE

(Street)

SOUTH ORANGE

NEW JERSEY

07079

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEPHROS INC [ NEPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/12/2026		A		2,418⁽¹⁾	A	$0	140,874	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.14							⁽²⁾	05/14/2034	Common Stock	7,323		7,323	D
Stock Option (Right to Buy)	$1.47							⁽³⁾	01/01/2035	Common Stock	7,050		7,050	D

Explanation of Responses:

1. Shares issued to reporting person in lieu of cash fees for board service.

2. Fully vested.

3. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.

	/s/ Arthur H. Amron	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR